Ongoing Clinical Trials for Respiratory Failure
There are currently 2 ongoing clinical trials investigating new treatment approaches for patients experiencing respiratory failure. These studies are exploring different medications to improve outcomes for patients requiring intensive care support, including ECMO therapy and mechanical ventilation.
Clinical trial locations
- Austria
- Denmark
Study on Anticoagulation Strategies with Heparin, Enoxaparin, and Argatroban for Patients with Respiratory or Circulatory Failure on ECMO Support
This trial is investigating different blood-thinning medications for patients who need support from ECMO, a machine that takes over the work of the lungs and sometimes the heart when they are not functioning well enough.
Who can participate: Patients must be over 18 years old and currently in an Intensive Care Unit. They must either need ECMO support or have started ECMO therapy within the last 12 hours.
Who cannot participate: The trial excludes patients with respiratory insufficiency, which means the lungs are not working well enough to meet the body’s needs. Patients with respiratory failure, where the lungs cannot provide enough oxygen or remove enough carbon dioxide, are also excluded. Additionally, patients with circulatory failure, when the heart and blood vessels cannot supply enough blood to the body’s organs, and those with Acute Respiratory Distress Syndrome cannot join the study.
What the trial is testing: The study compares three different medications used to prevent blood clots during ECMO therapy: Unfractionated Heparin, Argatroban, and Enoxaparin (a low-molecular-weight heparin). Blood clots are a common and serious risk during ECMO treatment, so finding the most effective medication is crucial.
Participants will be randomly assigned to receive one of these three medications. Those receiving heparin or argatroban will get the medication through an intravenous infusion directly into a vein. Those receiving enoxaparin will get injections under the skin. Throughout the study, patients will be closely monitored for blood clots, such as pulmonary embolism and deep vein thrombosis, as well as any bleeding events. The trial aims to determine which medication best prevents blood clots without causing significant bleeding, helping improve treatment strategies for patients requiring ECMO support in the future.
Study on the Effects of Iloprost Trometamol in Patients with Infectious Lung Disease on Mechanical Ventilation
This trial is studying a condition called infectious pulmonary endotheliopathy, which affects the blood vessels in the lungs and can lead to severe breathing problems in patients with lung infections.
Who can participate: Patients must be adults (18 years or older) in intensive care with a suspected lung infection. They must require mechanical ventilation, a machine that helps with breathing, and this support should have started less than 24 hours before entering the study. Additionally, they must have a specific level of a substance called an endothelial biomarker in their blood, which should be 4 ng/mL or higher. This marker is related to the cells lining blood vessels.
Who cannot participate: The study excludes patients with serious infections unrelated to the lungs, those with a history of severe allergic reactions to similar medications, and pregnant or breastfeeding women. Individuals with severe liver or kidney problems, certain heart conditions that could worsen with the study medication, or those who have had recent major surgery are also excluded. Patients currently participating in another clinical trial, those with a history of drug or alcohol abuse, or individuals unable to give informed consent cannot participate.
What the trial is testing: The study is exploring the effects of Iloprost, a medication given as a continuous infusion directly into the bloodstream over 72 hours. The trial will compare the effects of Iloprost to a placebo to determine if it can help reduce the risk of death within 28 days for patients on mechanical ventilation due to infectious lung disease.
Iloprost works by improving blood flow in the lungs and reducing inflammation in blood vessel walls. At the molecular level, it mimics a natural compound called prostacyclin, which dilates blood vessels and prevents blood platelets from clumping together. During the study, patients will be closely monitored to assess survival rates over 28 days and up to 90 days. Researchers will also track the need for additional medical support, such as vasopressors (medications that help maintain blood pressure) or continued mechanical ventilation, and any serious side effects. The goal is to find a potential new treatment option that can improve outcomes for patients with severe lung infections requiring intensive care.
Summary
These two clinical trials represent important research efforts to improve care for patients experiencing respiratory failure in different contexts. The first trial in Austria focuses on preventing blood clots in patients requiring ECMO support, comparing three well-established anticoagulation medications to determine the safest and most effective approach. The second trial in Denmark takes a different approach, investigating whether Iloprost can improve survival rates in patients with infectious lung disease who need mechanical ventilation.
Both studies address critical challenges in intensive care medicine where treatment strategies can significantly impact patient survival and recovery. The Austrian study aims to optimize existing therapy by comparing different blood-thinning medications, while the Danish study explores a newer therapeutic approach targeting blood vessel inflammation in infected lungs. Together, these trials contribute to expanding treatment options for patients with severe respiratory conditions requiring intensive care support.
